• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

What do experts wish patients knew about eye health? Part 2


Experts in the field weigh in on and give opinions on the question "What do you wish patients knew about eye health."

Our team spoke with several researchers and industry professionals at the 2023 American Society of Retina Specialists meeting in Seattle, Washington. We asked, "What do you wish patients knew about eye health?" Here's what Shawn Kavoussi, MD, Michael Ip, MD, Megan Baldwin, MD, had to say!

Video Transcript

Editor's note - This transcript has been edited for clarity.

Shawn Kavoussi, MD:

I wish they knew more about wearing eye protection for various common activities. I can think of one patient who had an unfortunate incident of open globe injury while mowing his lawn, and while wearing sunglasses. So I wish patients would consider using wraparound safety goggles for a variety of activities that may pose some risks.

Michael Ip, MD:

Eye health is very important with respect to knowing that there are many very effective treatments out there that are currently available...in terms of advancing the field. Currently in the field, there are many FDA-approved, community standard treatments that are highly effective for common diseases such as neovascular age-related macular degeneration and diabetic retinopathy. The earlier the patient has come to attention to the medical professionals, the better the results are. I do wish that a lot of patients understood that. Earlier detection and early treatment leads to better outcomes.

Megan Baldwin, MD:

I think that many patients are focused on obviously, improving the outcomes. They absolutely want to have the best possible gains in their visual acuity so they can go about their normal, everyday lives. I think that a lot of the focus of many of the drug development programs right now just on treatment burden, [and] I think that patients themselves really just want to have the best possible efficacy outcomes so that they can continue to maintain independent lives, reduce burden on caregivers, etc. Let's keep pushing the frontiers of new science and new approaches so that we can actually achieve that for them.

Related Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
© 2024 MJH Life Sciences

All rights reserved.